Cystatin C and Cardiovascular Risk in the General Population;Cistatina C y riesgo cardiovascular en población general

Revista Espanola de Cardiologia

Volumn 63, Issue 4, 2010, Pages 415-422

  Cepeda, Javier ^a   Tranche Iparraguirre, Salvador ^b   Marín Iranzo, Rafael ^c   Fernández Rodríguez, Eloy ^d   Riesgo García, Alba ^c   García Casas, Juan ^e   Hevia Rodríguez, Eduardo ^f  

^a HOSPITAL SANTOS REYES   (Spain)

^b Ctro de Salud El Cristo Servicio de Salud del Principado de Asturias (SESPA) Oviedo Asturias Es   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL DE CABUEÑES   (Spain)

^e UNIVERSITY OF OVIEDO   (Spain)

^f Centro de Salud Cabañaquinta SESPA Mieres Asturias España   (Spain)

Author keywords

Cardiovascular disease; Cardiovascular risk; Chronic kidney disease; Cystatin C; Estimated glomerular filtration rate

Indexed keywords

C REACTIVE PROTEIN; CYSTATIN C; FIBRINOGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; TRIACYLGLYCEROL;

ADULT; AGED; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DESCRIPTIVE RESEARCH; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NEPHELOMETRY; PREVALENCE; SYSTOLIC BLOOD PRESSURE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; CYSTATIN C; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 77950562843     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(10)70062-2     Document Type: Article

References (27)

1. Yusuf S., Hawken S., Oupuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modificable risk factors associaten with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364 (2004) 937-952
2. Gómez M., Valle V., Arós F., Sanz G., Sala J., Fiol M., et al. LDL oxidada, lipoproteína (a) y otros factores de riesgo emergentes en el infarto agudo de miocardio (Estudio FORTIAM). Rev Esp Cardiol 62 (2009) 373-382
3. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation 108 (2003) 2154-2169
4. Stevens L.A., and Levey A.S. Clinical implications for estimating equations for glomerular filtration rate. Ann Intern Med 141 (2004) 959-961
5. Dharnidharka V.R., Kwon C., and Stevens G. Serum cystatin C is superior to serum creatinina as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40 (2002) 221-226
6. Shlipak M.G., Katz R., Sarnak M.J., Fied L.F., Newman A.B., Stehman-Breen C., et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145 (2006) 237-246
7. Shlipak M.G., Sarnak M.J., Katz R., Fried L.F., Seliger S.L., Newman A.B., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352 (2005) 2049-2060
8. Otero A., Gayoso P., García F., De Francisco A.L., and On behalf of the EPIRCE study group. Epidemiology of chronic renal disease in the Galician population: results of the pilot Spanish EPIRCE study. Kidney Int 99 (2005) S16-S19
9. Uhlmann E.J., Hock K.G., Issitt C., Sneeringer M.R., Cervelli D.R., Gorman R.T., et al. Reference intervals for plasma cystatin C int healthy volunteers and renal patients, as measured by the Dade Behring BN II system, and correlation with creatinine. Clin Chem 47 (2001) 2031-2033
10. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis. 2002;39:S1-266.
11. Méndez Bailón M., Romero Román C., Conthe Gutiérrez P., and Audibert Mena L. Determinación de cistatina C en pacientes de edad avanzada con insuficiencia cardiaca. Med Clin (Barc) 127 (2002) 636-641
12. Martín M.V., Barroso S., Herraez O., and De Sande F. Cistatina C como estimador de la función renal en estadios avanzados de enfermedad renal crónica. Nefrología 26 (2006) 433-438
13. Rodilla E., Costa J.A., Lahiguera F.P., González C., Miralles A., and Pascual J.M. Relación de la Cistatina C con otros parámetros de riesgo vascular en pacientes con hipertensión arterial. Med Clin (Barc) 130 (2008) 1-5
14. Köttgen A., Selvia E., Stevens L.A., Levey A.S., Lente V.F., and Coresh J. Serum cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 51 (2008) 385-394
15. Parikh N., Hwang S.J., Yang Q., Larson M., Guo C.Y., Robins S., et al. Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study). Am J Cardiol 102 (2008) 1194-1198
16. Soriano Cabrera S. Definición y clasificación de los estadios de la enfermedad renal crónica. Prevalencia. Claves para el diagnóstico precoz. Factores de riesgo de enfermedad renal crónica. Nefrología 24 (2004) 27-34
17. Robles N.R., Barroso S., and Ruiz-Calero R. Papel de la cistatina C en la valoración de la función renal y su relación con el riesgo cardiovascular. Hipertensión 24 (2007) 201-208
18. Knight E.L., Verhave J.C., Spiegelman D., Hillege H.L., De Zeeuw D., Curhan G.C., et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65 (2004) 1416-1421
19. Ix J.H., Shlipak M.G., Chertow G.M., and Whooley M.A. Association of cyctatin C with mortality, cardiovascular events and incident heart failure among persons with coronary heart disease. Circulation 115 (2007) 173-179
20. García Acuña J.M., González-Babarro E., Grigorian Shamagian L., Peña-Gil C., Vidal Pérez R., López-Lago A.M., et al. La cistatina C aporta más información que otros parámetros de función renal en la estratificación del riesgo de los pacientes con síndrome coronario agudo. Rev Esp Cardiol 62 (2009) 510-519
21. Keller C., Katz R., Cushman M., Fried L., and Shlipak M. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: A cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 9 (2008) 9
22. Stevens L.A., Schmid C.H., Greene T., Li L., Beck G.J., Joffe M.M., et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 75 (2009) 652-660
23. Roos J.F., Doust J., Tett S.E., and Kirkpatrick C.M. Diagnostic accuracy of cystatin-C compared to serum creatinina for the estimation of renal disfunction in adults and children. A meta-analysis. Clinical Biochemistry 40 (2007) 383-391
24. Servais A., Giral P., Bernard M., Bruckert E., Deray G., and Isnard Bagnis C. Is serum cystatin C a reliable marker for metabolic syndrome?. Am J Med 121 (2008) 426-432
25. Kestenbaum B., Rudser K.D., Boer I.H., Peralta C.A., Fried L.F., Shlipak M.G., et al. Differences in kidney function and incident hipertension: The multi-ethnic study of atherosclerosis. Ann Intern Med 148 (2008) 501-508
26. Donahue R.P., Stranges S., Rejman K., Rafalson L.B., Dmochowski J., and Trevisan M. Elevated cystatin C concentration and progression to prediabetes: the Western New York study. Diabetes Care 30 (2007) 1724-1729
27. Perkins B.A., and Krolewski A.S. Early Nephropathy in type 1 diabetes: A new perspective on who will and who will not progress. Curr Diab Rep 5 (2005) 455-563